<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928600</url>
  </required_header>
  <id_info>
    <org_study_id>CES 171-17</org_study_id>
    <nct_id>NCT03928600</nct_id>
  </id_info>
  <brief_title>Labor Induction With a Combined Method (Pharmacologic and Mechanical): Randomized Controlled Trial</brief_title>
  <official_title>Labor Induction With a Combined Method (Pharmacologic and Mechanical): Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Hospitalar De São João, E.P.E.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Hospitalar De São João, E.P.E.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Labor induction is a common pregnancy procedure worldwide. Both mechanical and pharmacologic
      agents are used for induction of labor. These agents reduce the incidence of cesarean
      delivery in women undergoing induction.

      Opposite to old studies of cervical ripening, some recent studies have shown promise in
      reducing labor time and risk of cesarean delivery with combination methods. The effectiveness
      of this procedure is of major clinical importance and has a large impact in our quotidian
      practice.

      The objective is to compare the effectiveness of a combined new method to current guidelines
      of our department
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed a randomized trial that will compare two groups: misoprostol-cervical Foley
      simultaneously and the current department guidelines (misoprostol alone/dinoprostone alone).

      Inclusion criteria: full-term (≥ 37 weeks of gestation), singleton, vertex-
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to delivery</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cesarean delivery rate</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to active labor</measure>
    <time_frame>3 days</time_frame>
    <description>defined as dilation of 6 cm or greater</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of delivery within 12 hours</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of delivery within 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean of maternal length of stay</measure>
    <time_frame>average 3 days</time_frame>
    <description>induction to discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>indication for cesarean delivery</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite maternal morbidity outcome</measure>
    <time_frame>6 weeks</time_frame>
    <description>third- or fourth-degree perineal laceration, blood transfusion, chorioamnionitis, endometritis, wound infection, venous thromboembolism, hysterectomy, intensive care unit admission or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of neonatal morbidities</measure>
    <time_frame>30 days</time_frame>
    <description>SDR, neonatal sepsis, blood transfusion, encephalopathy hypoxic-ischemic, intraventricular hemorrhage of grade III/IV</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Labor, Induced</condition>
  <condition>Cervical Ripening</condition>
  <arm_group>
    <arm_group_label>Combined method induction group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25 micrograms misoprostol vaginal applied placed along with cervical Foley (team will repeat misoprostol application each 4 hours till 6 doses of misoprostol)
After 4 hours of last misoprostol initiate oxytocin.
Cervical Foley will be removed after 12h of placement or when fails out.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Current department guidelines group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Following current department guidelines, as usual, with the method considered more suitable.
If they opted for vaginal misoprostol, team will insert 25micrograms, repeat application 4/4h, until 150micrograms, after last misoprostol, wait 4 hours before initiating oxytocin.
If option is vaginal dinoprostone the insert of 10mg is removed after 24h in place.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cervical Foley combined with Misoprostol</intervention_name>
    <description>Placement of cervical Foley catheter along with application of vaginal misoprostol 25ug that will be repeated 4/4h until 150ug</description>
    <arm_group_label>Combined method induction group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone 10mg insert OR</intervention_name>
    <description>Application for 24h of Dinoprostone 10mg insert</description>
    <arm_group_label>Current department guidelines group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Application of vaginal misoprostol 25ug 4/4h until 150ug</description>
    <arm_group_label>Current department guidelines group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  full-term (≥ 37 weeks of gestation)

          -  singleton

          -  vertex-presenting gestations

          -  with no contraindication to vaginal delivery

          -  intact membranes

          -  Bishop score &lt; 7 and cervical dilation ≤2 cm

        Exclusion Criteria:

          -  contraindication for misoprostol

          -  history of previous caesarean

          -  rupture of membranes,

          -  fetal or maternal morbidities (fetal major abnormalities, FIGO definition of
             pathological CTG, HELLP syndrome, preeclampsia or hypertension with severe features,
             fetal growth restriction)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rita P Valente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Hospitalar São João, Porto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Hospitalar São João</name>
      <address>
        <city>Porto</city>
        <zip>4100</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Portugal</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 4, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <last_update_submitted>March 8, 2020</last_update_submitted>
  <last_update_submitted_qc>March 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Hospitalar De São João, E.P.E.</investigator_affiliation>
    <investigator_full_name>Rita Polónia Valente</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>induction of labor</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>combined methods</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

